Medigen Biotechnology (ROCO:3176) Long-Term Debt: NT$1,117 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
55 GF Score
Price NT$31.10
GF Value NT$36.76
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Medigen Biotechnology Long-Term Debt?

Medigen Biotechnology ROCO:3176 -2.96% 55 Long-Term Debt is NT$1,117 Mil as of Mar. 2026. GuruFocus rates ROCO:3176 with a GF Score™ of 55/100 and a GF Value™ of NT$36.76 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Medigen Biotechnology's Long-Term Debt for the quarter that ended in Mar. 2026 was NT$1,117 Mil.

Medigen Biotechnology's quarterly Long-Term Debt declined from Sep. 2025 (NT$434 Mil) to Dec. 2025 (NT$421 Mil) but then increased from Dec. 2025 (NT$421 Mil) to Mar. 2026 (NT$1,117 Mil).

Medigen Biotechnology's annual Long-Term Debt declined from Dec. 2023 (NT$449 Mil) to Dec. 2024 (NT$411 Mil) but then increased from Dec. 2024 (NT$411 Mil) to Dec. 2025 (NT$421 Mil).

Medigen Biotechnology  (ROCO:3176) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Medigen Biotechnology Long-Term Debt Related Terms

Medigen Biotechnology Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Long-Term Debt Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 470.77 2,129.16 449.10 411.25 421.32

Medigen Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 401.86 392.42 433.88 421.32 1,116.78
ROCO:3176
55GF Score
Medigen Biotechnology Corp ROCO:3176
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$1,117 Mil mean?
Medigen Biotechnology (ROCO:3176) has a Long-Term Debt of NT$1,117 Mil as of Mar. 2026.
Is Medigen Biotechnology's Long-Term Debt too high?
Medigen Biotechnology's current Long-Term Debt is NT$1,117 Mil. Overall, Medigen Biotechnology has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Long-Term Debt compare to VRTX and REGN?
Medigen Biotechnology's Long-Term Debt of NT$1,117 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Medigen Biotechnology's current Long-Term Debt is NT$1,117 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$36.76, compared to a current price of NT$31.10 — trading 15.4% below its estimated fair value. The current Long-Term Debt is NT$1,117 Mil. Medigen Biotechnology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Long-Term Debt is NT$1,117 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$31.10 is trading 15.4% below its estimated GF Value™ of NT$36.76. GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.

Key valuation signals for ROCO:3176:

  • Long-Term Debt: NT$1,117 Mil
  • GF Value™: NT$36.76 vs. price of NT$31.10 (15.4% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
55GF Score

Get the complete analysis for ROCO:3176

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.10
Price
NT$36.76
GF Value